Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Evvy raises a $40 million Series B led by Catalio Capital Management to further women’s health research using vaginal microbiome data. Its at-home sequencing test serves more than 100,000 patients and works with 3,000 practitioners, while its platform provides clinician-reviewed results and personalized care. Evvy is building a dataset linking microbiome biology, symptoms, interventions, and outcomes, and is studying connections to fertility, including through a prospective study in IVF clinics.
Evvy raises $40 million in Series B funding to scale its precision diagnostics and care platform for women’s health. Its at-home vaginal microbiome test uses metagenomic sequencing, while EvvyAI analyzes results and matches patients with personalized prescription treatment plans. The company says its technology has served more than 100,000 patients through 3,000 medical practitioners, and it plans to use the funding to validate AI-enabled care models, starting with fertility issues.
